In this free webinar, gain insights into the complex challenges
of conducting clinical trials for developmental and epileptic
encephalopathy. Attendees will learn about approaches for data
collection across large geographic areas. The featured speaker will
discuss the factors to consider when selecting cognitive and
behavioral endpoints. The speaker will also share approaches for
determining minimally clinically important difference.
TORONTO, Sept. 17,
2024 /PRNewswire-PRWeb/ -- Clinical trials in
patients with developmental and epileptic encephalopathy (DEE)
present considerable challenges for research teams, including the
difficulty in identifying patients, the large geographic spread of
patients and the need for measurements that can catch even the
smallest degree of change in behavior or function.
It becomes a near impossible task to find
sites that are in the appropriate geographies and have the level of
expertise to administer the scales necessary for signal
detection.
One byproduct of these challenges is the difficulty that arises
in site selection. It becomes a near impossible task to find sites
that are in the appropriate geographies and have the level of
expertise to administer the scales necessary for signal
detection.
In this webinar, the expert speaker will address these obstacles
and share solutions. She will describe approaches to collect data
across large geographic areas and in locations that do not have
specialized or experienced raters. She will share factors to
consider when selecting cognitive and behavioral endpoints for DEE
trials, including perspectives from regulatory agencies.
Moreover, she will describe the application of developmental
assessments (e.g., Bayley-4) and behavioral scales (e.g., the
Vineland-3), along with approaches
for determining minimally clinically important difference (MCID)
with these measures in DEE populations.
Register for this webinar to gain insights into the complex
challenges of conducting clinical trials for developmental and
epileptic encephalopathy.
Join Pamela Ventola, PhD, Chief
Science Officer, Cogstate, for the live webinar on Thursday, October 3, 2024, at 11am EDT (4pm
BST/UK).
For more information, or to register for this event, visit
Developmental & Epileptic Encephalopathy (DEE) Trials:
Optimizing Endpoints, Determining MCID, and Enhancing Trial Data
Quality.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading
provider of educational webinars and digital content to the global
life science, food, healthcare and medical device communities.
Every year, thousands of industry practitioners (from
pharmaceutical, biotechnology, food, healthcare and medical device
companies, private & academic research institutions, healthcare
centers, etc.) turn to Xtalks for access to quality content. Xtalks
helps professionals stay current with industry developments,
regulations and jobs. Xtalks webinars also provide perspectives on
key issues from top industry thought leaders and service
providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit
https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416)
977-6555 x371, vkovacevic@xtalks.com, https://xtalks.com
View original content to download
multimedia:https://www.prweb.com/releases/developmental--epileptic-encephalopathy-dee-trials-optimizing-endpoints-determining-mcid-and-enhancing-trial-data-quality-upcoming-webinar-hosted-by-xtalks-302250641.html
SOURCE Xtalks